A 28-year-old man with HIV infection (CD4 count 85 cells/μL) presents with severe vesicular lesions involving the perioral region, upper lip, and extending into the oral mucosa. The lesions are extremely painful and have been present for 10 days despite self-initiated topical acyclovir. On examination, erosions with crusting are seen, and some lesions show hemorrhagic fluid. What is the most appropriate next step in management?

Explanation

## Management of Severe HSV in Advanced HIV ### Clinical Context: Severe Immunosuppression The patient has: - **CD4 count 85 cells/μL** — profound immunosuppression (normal >500) - **Severe HSV infection** — extensive perioral and intraoral involvement with hemorrhagic erosions - **Treatment failure** — no response to topical acyclovir after 10 days **Key Point:** In advanced HIV (CD4 <50–100), HSV often becomes severe, disseminated, and may show **acyclovir resistance** due to viral thymidine kinase (TK) mutations or viral DNA polymerase mutations. ### Why Intravenous Acyclovir is Indicated | Scenario | Recommended Therapy | Rationale | |----------|-------------------|----------| | **Mild HSV, CD4 >200** | Oral acyclovir or valacyclovir | Adequate oral bioavailability | | **Moderate HSV, CD4 50–200** | Oral valacyclovir or IV acyclovir | Consider IV if severe or slow response | | **Severe/disseminated HSV, CD4 <50** | **IV acyclovir 10–15 mg/kg q8h** | High-dose IV ensures adequate CNS/mucosal penetration; assess for resistance | | **Acyclovir-resistant HSV** | **Foscarnet 40 mg/kg IV q8h** | TK-deficient or polymerase mutants | **High-Yield:** Intravenous acyclovir achieves higher serum and tissue concentrations than oral formulations and is essential when: 1. CD4 <50 cells/μL 2. Severe or disseminated disease 3. Failure of oral therapy 4. Suspected acyclovir resistance ### Pathophysiology of Acyclovir Resistance in HIV Two main mechanisms: 1. **TK-deficient mutants** (most common) — lack viral thymidine kinase, cannot phosphorylate acyclovir to its active form 2. **Polymerase mutants** — altered viral DNA polymerase with reduced acyclovir sensitivity Resistance emerges with prolonged or repeated acyclovir exposure in severely immunocompromised hosts. ### Clinical Pearl The **hemorrhagic fluid** and **extensive erosions** in a CD4 <100 patient are red flags for severe HSV that may not respond to standard oral therapy. Systemic symptoms (fever, malaise) and potential dissemination to esophagus or CNS make IV therapy mandatory. ### Next Steps After IV Acyclovir Initiation 1. **Viral culture or PCR** from lesion fluid to confirm HSV and test for resistance 2. **If acyclovir-resistant:** Switch to **foscarnet 40 mg/kg IV every 8 hours** or **cidofovir** 3. **Immune reconstitution:** Ensure patient is on antiretroviral therapy (ART); CD4 recovery is the ultimate goal 4. **Prophylaxis:** Once CD4 recovers to >200 on ART, continue prophylactic acyclovir or valacyclovir **Mnemonic:** **SEVERE HSV in AIDS** = **S**evere disease, **E**xtensive lesions, **V**iral resistance likely, **E**nsure IV therapy, **R**esistance testing, **E**nsure ART compliance.